Mutational K-ras activation arises very frequently in epithelial cancers, with highest frequencies prevalent in lung, pancreatic and colorectal cancers. K-ras mutant cancers are highly aggressive with extremely poor prognoses and high mortality rates. Unfortunately, these cancers remain highly refractory to both conventional and targeted therapeutics. Additionally, pharmacological inhibition of K-Ras protein has proven to be difficult to achieve clinically. My initial aim was to model """"""""addiction"""""""" to mutant K-ras in the hopes of identifying molecular determinants that define the """"""""Kras-addicted"""""""" state with the ultimate aim of identifying candidate therapeutic targets. Using K-ras-specific shRNAs to deplete K-Ras protein in lung and pancreatic cancer cell lines harboring mutant K-ras, I identified two classes - those that are """"""""addicted"""""""" to or dependent on K- Ras activity for viability and those that are K-Ras independent. By comparing whole genome expression profiles for these two classes, I derived a gene expression signature associated with K-Ras dependency. Several genes represented in this signature were required to maintain the viability of K-Ras dependent cancer cells, implicating them as candidate therapeutic targets in Kras mutant cancers. This proposal hopes to extend these initial findings by identifying lineage or tissue-specific anti-apoptotic genes in Kras mutant cancers, with the hopes of revealing novel context-specific therapeutic targets. Tissue-specific K-Ras dependency signatures will be generated for Kras mutant lung, pancreatic and colorectal cancers. Genes representing pharmacologically tractable targets will then be validated for their potential as candidate therapeutic targets. Cell biological and biochemical analyses will be performed to determine if there are tissue-specific biological or signaling features that contribute to the general phenomenon of K-Ras dependency. Finally, available pharmacological inhibitors against these targets will be tested for efficacy in pre-clinical mouse models of K-ras-driven tumorigenesis.

Public Health Relevance

Project Relevance Kras is the most frequently mutated oncogene in solid tumors with highest frequencies seen in lung, pancreatic and colorectal cancers. I propose to generate gene expression signatures for lung, pancreatic and colorectal cancers in the hopes of identifying novel therapies for each of these cancers, which are very difficult to treat with current chemotherapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Transition Award (R00)
Project #
4R00CA149169-03
Application #
8461312
Study Section
Special Emphasis Panel (NSS)
Program Officer
Watson, Joanna M
Project Start
2010-06-08
Project End
2015-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
3
Fiscal Year
2012
Total Cost
$249,000
Indirect Cost
$96,877
Name
Boston University
Department
Type
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Grant, Trevor J; Mehta, Anita K; Gupta, Anamika et al. (2017) STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. Oncotarget 8:78556-78572
Mehta, Anita K; Hua, Kevin; Whipple, William et al. (2017) Regulation of autophagy, NF-?B signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells. Sci Signal 10:
Anderson, N M; Li, D; Peng, H L et al. (2016) The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis. Leukemia 30:1365-74
McNew, Kelsey L; Whipple, William J; Mehta, Anita K et al. (2016) MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling. Mol Cancer Res 14:1204-1216
Brandl, Miriam B; Pasquier, Eddy; Li, Fuhai et al. (2014) Computational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancer. Mol Oncol 8:1548-60
Liu, Suling; Cong, Yang; Wang, Dong et al. (2014) Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports 2:78-91
Sahin, Ozgur; Wang, Qingfei; Brady, Samuel W et al. (2014) Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Res 24:542-59
Glasgow, Stacey M; Laug, Dylan; Brawley, Vita S et al. (2013) The miR-223/nuclear factor I-A axis regulates glial precursor proliferation and tumorigenesis in the CNS. J Neurosci 33:13560-8
Li, Fuhai; Yin, Zheng; Jin, Guangxu et al. (2013) Chapter 17: bioimage informatics for systems pharmacology. PLoS Comput Biol 9:e1003043
Cheng, Jie; Zhu, Xiaoping; Cheng, Hao et al. (2013) A quantitative analysis of F-actin features and distribution in fluorescence microscopy images to distinguish cells with different modes of motility. Conf Proc IEEE Eng Med Biol Soc 2013:136-9

Showing the most recent 10 out of 19 publications